SAEM GRACE:苯巴比妥用于急诊科酒精戒断管理:直接证据的系统综述
该系统综述按PICO问题检索成人急诊酒精戒断患者使用苯巴比妥(含辅助用药)对比苯二氮䓬类或无干预的直接证据。从70篇潜在相关文献中纳入7项研究:3项回顾性队列、2项回顾性病历审查、2项随机对照试验(一项单药、一项辅助用药)。回顾性队列显示苯巴比妥治疗与后续急诊就诊几率降低相关,病历审查显示苯巴比妥与更高出院率相关;两项随机对照试验中苯巴比妥多数结局与苯二氮䓬类无显著差异,但辅助苯巴比妥与更低的苯二氮䓬用量和重症监护室入住相关。研究设计异质且数量少,无法定量合成。
要点
- 系统综述纳入7项研究:3项回顾性队列、2项回顾性病历审查、2项随机对照试验(一项单药、一项辅助用药)。
- 回顾性队列研究显示,急诊酒精戒断使用苯巴比妥治疗与后续急诊就诊几率降低相关。
- 回顾性病历审查显示,苯巴比妥与苯二氮䓬类单药治疗相比与更高出院率相关。
- 两项随机对照试验中,苯巴比妥在多数结局上与苯二氮䓬类无显著差异。
- 辅助苯巴比妥与更低的苯二氮䓬用量和重症监护室入住相关;研究异质且数量少,无法定量合成。
适用人群与场景
- 成人(≥18岁)到急诊科就诊的酒精戒断患者。
研究设计与关键结果
- 系统综述按PICO问题检索:人群为成人(≥18岁)急诊酒精戒断,干预为苯巴比妥(包括辅助用药),对照为苯二氮䓬类或无干预,结局为酒精戒断并发症、入住监护病房、症状控制、不良反应和辅助用药。
- 从70篇潜在相关文献中纳入7项研究:3项回顾性队列研究、2项回顾性病历审查、2项随机对照试验(一项考察苯巴比妥单药治疗,一项考察辅助苯巴比妥)。
- 回顾性队列研究显示,苯巴比妥治疗酒精戒断与后续急诊就诊几率降低相关。
- 回顾性病历审查显示,苯巴比妥与苯二氮䓬类单药治疗相比与更高出院率相关。
- 两项随机对照试验中,苯巴比妥在多数结局上与苯二氮䓬类无显著差异,但辅助苯巴比妥与更低的苯二氮䓬用量和重症监护室入住相关。
- 研究设计异质且研究数量少,无法进行定量合成。
证据类型、等级与局限
- 证据类型:系统综述,纳入3项回顾性队列研究、2项回顾性病历审查和2项随机对照试验。
- 局限:研究设计异质且研究数量少,无法进行定量合成;需要更多随机对照试验和其他方法学严谨的研究以获得更明确的直接证据。
对床旁实践的改变
- 现有直接证据总体提示苯巴比妥用于急诊酒精戒断是合理且适当的方法(作者认为)。
- 苯巴比妥在随机对照试验中多数结局与苯二氮䓬类无显著差异;辅助苯巴比妥与更低的苯二氮䓬用量和重症监护室入住相关。
- 需要更多随机对照试验和其他方法学严谨的研究以获得更明确的直接证据(作者认为)。
指南或共识出处
- SAEM GRACE系统综述(Acad Emerg Med)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Alcohol withdrawal syndrome (AWS) is a commonly presenting condition in the emergency department (ED) and can have severe complications, including mortality. Benzodiazepines are first-line medications for treating AWS but may be unavailable or insufficient. This systematic review evaluates the direct evidence assessing the utility of phenobarbital for treating AWS in the ED.
METHODS: A systematic search was conducted and designed according to the patient-intervention-comparator-outcome (PICO) question: (P) adults (≥18 years old) presenting to the ED with alcohol withdrawal; (I) phenobarbital (including adjunctive); (C) benzodiazepines or no intervention; and (O) AWS complications, admission to a monitored setting, control of symptoms, adverse effects, and adjunctive medications. Two reviewers independently assessed articles for inclusion and conducted risk of bias assessments for included studies.
RESULTS: From 70 potentially relevant articles, seven studies met inclusion criteria: three retrospective cohort studies, two retrospective chart reviews, and two randomized controlled trials (RCTs), one examining phenobarbital monotherapy and one examining adjunctive phenobarbital. Across the retrospective cohort studies, treatment of AWS with phenobarbital resulted in lower odds of a subsequent ED visit. The retrospective chart reviews indicated that phenobarbital was associated with higher discharge rate compared to benzodiazepine-only treatments. For the two RCTs, phenobarbital did not differ significantly from benzodiazepine for most outcomes, although concomitant treatment with phenobarbital was associated with lower benzodiazepine use and intensive care unit admission. The heterogeneous designs and small number of studies prevented quantitative synthesis.
CONCLUSIONS: Relatively few studies provide direct evidence on the utility of phenobarbital for AWS in the ED, but the evidence that exists generally suggests that it is a reasonable and appropriate approach. Additional RCTs and other methodologically rigorous investigations are needed for more definitive direct evidence.
参考来源
- Punia K, Scott W, Manuja K, et al. SAEM GRACE: Phenobarbital for alcohol withdrawal management in the emergency department: A systematic review of direct evidence. Acad Emerg Med. 2023. PMID: 37589203. doi:10.1111/acem.14788
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。